204 related articles for article (PubMed ID: 25170636)
1. A combined prognostic serum interleukin-8 and interleukin-6 classifier for stage 1 lung cancer in the prostate, lung, colorectal, and ovarian cancer screening trial.
Ryan BM; Pine SR; Chaturvedi AK; Caporaso N; Harris CC
J Thorac Oncol; 2014 Oct; 9(10):1494-503. PubMed ID: 25170636
[TBL] [Abstract][Full Text] [Related]
2. Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer.
Pine SR; Mechanic LE; Enewold L; Chaturvedi AK; Katki HA; Zheng YL; Bowman ED; Engels EA; Caporaso NE; Harris CC
J Natl Cancer Inst; 2011 Jul; 103(14):1112-22. PubMed ID: 21685357
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of preoperative serum concentrations of interleukin-6 as a prognostic marker in patients with esophageal cancer.
Maeda Y; Takeuchi H; Matsuda S; Okamura A; Fukuda K; Miyasho T; Nakamura R; Suda K; Wada N; Kawakubo H; Kitagawa Y
Esophagus; 2020 Jul; 17(3):279-288. PubMed ID: 31845119
[TBL] [Abstract][Full Text] [Related]
4. Research on the relationship between serum levels of inflammatory cytokines and non-small cell lung cancer.
Song XY; Zhou SJ; Xiao N; Li YS; Zhen DZ; Su CY; Liu ZD
Asian Pac J Cancer Prev; 2013; 14(8):4765-8. PubMed ID: 24083740
[TBL] [Abstract][Full Text] [Related]
5. Association of inflammatory biomarkers with lung cancer in North Indian population.
Gaur P; Bhattacharya S; Kant S; Kushwaha R; Garg R; Singh G; Pandey S; Sharma S
Afr Health Sci; 2019 Jun; 19(2):2147-2155. PubMed ID: 31656499
[TBL] [Abstract][Full Text] [Related]
6. Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening.
Sestini S; Boeri M; Marchiano A; Pelosi G; Galeone C; Verri C; Suatoni P; Sverzellati N; La Vecchia C; Sozzi G; Pastorino U
Oncotarget; 2015 Oct; 6(32):32868-77. PubMed ID: 26451608
[TBL] [Abstract][Full Text] [Related]
7. Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy.
Chang CH; Hsiao CF; Yeh YM; Chang GC; Tsai YH; Chen YM; Huang MS; Chen HL; Li YJ; Yang PC; Chen CJ; Hsiung CA; Su WC
Int J Cancer; 2013 May; 132(9):1977-85. PubMed ID: 23034889
[TBL] [Abstract][Full Text] [Related]
8. Identification of serum inflammatory markers as classifiers of lung cancer mortality for stage I adenocarcinoma.
Meaney CL; Zingone A; Brown D; Yu Y; Cao L; Ryan BM
Oncotarget; 2017 Jun; 8(25):40946-40957. PubMed ID: 28402963
[TBL] [Abstract][Full Text] [Related]
9. Predictive and prognostic value of LPS-stimulated cytokine secretion in metastatic non-small cell lung cancer.
Vlachostergios PJ; Gioulbasanis I; Ghosh S; Tsatsanis C; Papatsibas G; Xyrafas A; Hatzidaki E; Vasiliou C; Kamposioras K; Agelaki S; Margioris AN; Nasi D; Georgoulias V; Papandreou CN
Clin Transl Oncol; 2013 Nov; 15(11):903-9. PubMed ID: 23463594
[TBL] [Abstract][Full Text] [Related]
10. Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer.
Tas F; Duranyildiz D; Argon A; Oğuz H; Camlica H; Yasasever V; Topuz E
Med Oncol; 2005; 22(4):353-8. PubMed ID: 16260852
[TBL] [Abstract][Full Text] [Related]
11. A Two-Gene Prognostic Classifier for Early-Stage Lung Squamous Cell Carcinoma in Multiple Large-Scale and Geographically Diverse Cohorts.
Noro R; Ishigame T; Walsh N; Shiraishi K; Robles AI; Ryan BM; Schetter AJ; Bowman ED; Welsh JA; Seike M; Gemma A; Skaug V; Mollerup S; Haugen A; Yokota J; Kohno T; Harris CC
J Thorac Oncol; 2017 Jan; 12(1):65-76. PubMed ID: 27613525
[TBL] [Abstract][Full Text] [Related]
12. Combining physical and biologic parameters to predict radiation-induced lung toxicity in patients with non-small-cell lung cancer treated with definitive radiation therapy.
Stenmark MH; Cai XW; Shedden K; Hayman JA; Yuan S; Ritter T; Ten Haken RK; Lawrence TS; Kong FM
Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):e217-22. PubMed ID: 22935395
[TBL] [Abstract][Full Text] [Related]
13. Development and validation of a prognostic model using blood biomarker information for prediction of survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiation or radiotherapy alone (NCT00181519, NCT00573040, and NCT00572325).
Dehing-Oberije C; Aerts H; Yu S; De Ruysscher D; Menheere P; Hilvo M; van der Weide H; Rao B; Lambin P
Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):360-8. PubMed ID: 20888135
[TBL] [Abstract][Full Text] [Related]
14. Pre-diagnostic serum levels of inflammation markers and risk of ovarian cancer in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial.
Trabert B; Pinto L; Hartge P; Kemp T; Black A; Sherman ME; Brinton LA; Pfeiffer RM; Shiels MS; Chaturvedi AK; Hildesheim A; Wentzensen N
Gynecol Oncol; 2014 Nov; 135(2):297-304. PubMed ID: 25158036
[TBL] [Abstract][Full Text] [Related]
15. Circulating inflammation markers and prospective risk for lung cancer.
Shiels MS; Pfeiffer RM; Hildesheim A; Engels EA; Kemp TJ; Park JH; Katki HA; Koshiol J; Shelton G; Caporaso NE; Pinto LA; Chaturvedi AK
J Natl Cancer Inst; 2013 Dec; 105(24):1871-80. PubMed ID: 24249745
[TBL] [Abstract][Full Text] [Related]
16. Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer.
Varkaris A; Katsiampoura A; Davis JS; Shah N; Lam M; Frias RL; Ivan C; Shimizu M; Morris J; Menter D; Overman M; Tran H; Heymach J; Chun YS; Vauthey JN; Calin G; Kopetz S
Br J Cancer; 2019 Feb; 120(3):340-345. PubMed ID: 30636774
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer.
Kwon KA; Kim SH; Oh SY; Lee S; Han JY; Kim KH; Goh RY; Choi HJ; Park KJ; Roh MS; Kim HJ; Kwon HC; Lee JH
BMC Cancer; 2010 May; 10():203. PubMed ID: 20465852
[TBL] [Abstract][Full Text] [Related]
18. Association between post-treatment circulating biomarkers of inflammation and survival among stage II-III colorectal cancer patients.
Hua X; Kratz M; Malen RC; Dai JY; Lindström S; Zheng Y; Newcomb PA
Br J Cancer; 2021 Sep; 125(6):806-815. PubMed ID: 34230610
[TBL] [Abstract][Full Text] [Related]
19. IL-6, IL-8 and TNF-α levels correlate with disease stage in breast cancer patients.
Ma Y; Ren Y; Dai ZJ; Wu CJ; Ji YH; Xu J
Adv Clin Exp Med; 2017; 26(3):421-426. PubMed ID: 28791816
[TBL] [Abstract][Full Text] [Related]
20. Serum IL-6 and IL-8 Correlate with Prognostic Factors in Ovarian Cancer.
Sanguinete MMM; Oliveira PH; Martins-Filho A; Micheli DC; Tavares-Murta BM; Murta EFC; Nomelini RS
Immunol Invest; 2017 Oct; 46(7):677-688. PubMed ID: 28872976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
